Pharmacokinetic Analysis of Irinotecan Plus Bevacizumab in Patients with Advanced Solid Tumors

PURPOSE: To evaluate the effect of bevacizumab on the pharmacokinetics (PK) of irinotecan and its active metabolite. Exploratory analyses of the impact of variability in uridine diphosphate glucuronosyltransferase 1A (UGT1A) genes on irinotecan metabolism and toxicity were conducted. METHODS: This w...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Denlinger, Crystal S., Blanchard, Rebecca, Xu, Lu, Bernaards, Coen, Litwin, Samuel, Spittle, Cynthia, Berg, Daniel J., McLaughlin, Susan, Redlinger, Maryann, Dorr, Andrew, Hambleton, Julie, Holden, Scott, Kearns, Anne, Kenkare-Mitra, Sara, Lum, Bert, Meropol, Neal J., O'Dwyer, Peter J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2009
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2746259/
https://ncbi.nlm.nih.gov/pubmed/19415281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-009-1008-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg